Provided by Tiger Trade Technology Pte. Ltd.

Quasi-New Stocks

680.54
-13.0145-1.88%
Number of Gainers:78
Number of Losers:65
Number of Flat:10
PE:- -
High:696.26
Open:693.57
Low:680.27
Close:693.55
Volume:112.85M
Turnover:3.36B
Market Cap:473.73B
Float Cap:359.31B

Loading ...

U.S. Stocks on the MOVE-Eli Lilly, Waystar, Sysco

Reuters
·
Yesterday

FTC Solar - Tracker Production for Sybella Creek Project Underway with Deliveries End 2026-Early 2027

THOMSON REUTERS
·
Yesterday

FTC Solar - Receives Notice to Begin Production for Sybella Creek Solar Farm in Australia

THOMSON REUTERS
·
Yesterday

Gartner® Names Kaltura the Company to Beat in the AI Race for Video Platform Services AI report, Published in August, 2026

GlobeNewswire
·
Yesterday

Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development

GlobeNewswire
·
Yesterday

Upexi to Host Fiscal Year 2026 Earnings Call on Thursday, September 17th at 5:30 P.M. ET

GlobeNewswire
·
Yesterday

Intel, Sandisk, Palantir, Coinbase, and More Stocks That Explain Today's Market

Dow Jones
·
Yesterday

Circle, Coinbase Fall Ahead Of Pivotal Procedural Vote On The CLARITY Act

Options & Short Sell
·
Yesterday

Vera Therapeutics Shares Gain on Positive Late-Stage Trial Results

Dow Jones
·
Yesterday

Vera Therapeutics Reports Successful TRUTAKNA Phase 3 Results

TIPRANKS
·
Yesterday

Top Premarket Gainers

MT Newswires Live
·
Yesterday

Crypto Equities Slide Ahead of Pivotal Senate Vote on Market Structure Bill

Stock News
·
Yesterday

Vera Therapeutics up 13% in pre-market at $38.63 after trutakna ORIGIN 3 data

TIPRANKS
·
Yesterday

Vera Therapeutics Gains After Kidney Disease Drug Meets Goals in Confirmatory Trial

Reuters
·
Yesterday

Vera Therapeutics’ trutakna meets all efficacy endpoints in IgAN trial

TIPRANKS
·
Yesterday

Vera Therapeutics, - Trutakna Demonstrates Favorable Safety Profile Generally Comparable to Placebo

THOMSON REUTERS
·
Yesterday

Vera Therapeutics, - Plans to Submit Supplemental Bla to FDA for Full Approval in Q4 2026

THOMSON REUTERS
·
Yesterday

Vera Therapeutics Announces Trutakna™ (Atacicept-Vymj) Stabilized Egfr and Prevented Kidney Disease Progression Through Two Years in Origin 3 Final Efficacy Analysis in Iga Nephropathy

THOMSON REUTERS
·
Yesterday

Vera Therapeutics, - Trutakna Meets All Prespecified Endpoints in Origin 3 Final Efficacy Analysis

THOMSON REUTERS
·
Yesterday

Citi ups Acumen target, opens ‘upside 90-day catalyst watch’

TIPRANKS
·
Yesterday